Sanofi updates on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
No safety signals related to the vaccine candidate were identified
No safety signals related to the vaccine candidate were identified
Offers affordable, high-quality solutions for diabetes care
Richard A. Gonzalez to retire from the board of directors effective July 1, 2025
The safety profile of Opdualag observed in this analysis was consistent with the known profiles of nivolumab and relatlimab
Total Income during Q3 FY25 stood at Rs. 527.37 crore as compared to Rs. 528.77 crore in Q3 FY24
Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries
Approval is based on positive data from the Phase 3 ECHELON-3 trial
The company will offer end-to-end services and solutions for the sector with a specific focus on sustainability
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Subscribe To Our Newsletter & Stay Updated